alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<PAGE>
Exhibit 13.1

                  CERTIFICATION BY THE CHIEF EXECUTIVE OFFICER

                           PURSUANT TO 18 U.S.C. 1350
      AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

The undersigned hereby certifies that, to his knowledge, (i) the Form 20-F filed
by Central Minera Corp. (the "Issuer") for the year ended June 30, 2005, fully
complies with the requirements of Section 13(a) or 15(d) of the Securities
Exchange act of 1934, and (ii) the information contained in that report fairly
present, in all material respects, the financial condition and results of
operations of the Issuer on the dates and for the periods presented therein.

                                        CENTRAL MINERA CORP.


                                        /s/ Michael Cytrynbaum
                                        ----------------------------------------
December 26, 2005                       Michael Cytrynbaum
                                        President and Chief Executive Officer
<PAGE>
                                                                      EXHIBIT 32


                Certification of the Principal Executive Officers
                           Pursuant to 18 U.S.C. 1350
                 (Section 906 of the Sarbanes-Oxley Act of 2002)

We, Morris H. Wheeler, the President and Chief Executive Officer and Robert W.
Pawlak, the Chief Financial Officer of Cohesant Technologies Inc. (the
"Company"), certify that to the best of our knowledge, based upon a review of
the Company's Annual Report on Form 10-KSB/A for the year ended November 30,
2003 (the "Report"):

                  (1) The Report fully complies with the requirements of Section
                  13(a) or 15(d) of the Securities Exchange Act of 1934, as
                  amended; and

                  (2) The information contained in the Report fairly presents,
                  in all material respects, the financial condition and results
                  of operations of the Company.

/s/ Morris H. Wheeler
    ------------------
Morris H. Wheeler
President and Chief Executive Officer
June 18, 2004

/s/ Robert W. Pawlak
    ----------------
Robert W. Pawlak
Chief Financial Officer
June 18, 2004
#### Surjit SINGH, Petitioner, v. Eric H. HOLDER, Jr., Attorney General, Respondent.

No. 08-71251.

United States Court of Appeals, Ninth Circuit.

Submitted Feb. 15, 2011.*

Filed March 9, 2011.

Jaspreet Singh, Esquire, Law Office of Jaspreet Singh, Jackson Heights, NY, for Petitioner.

*685Linda Y. Cheng, Trial, OIL, Susan Houser, Carl Henry McIntyre, Jr., Assistant Director, DOJ-U.S. Department of Justice, Washington, DC, Chief Counsel Ice, Office of the Chief Counsel Department of Homeland Security, San Francisco, CA, for Respondent.

Before: CANBY, FERNANDEZ, and M. SMITH, Circuit Judges.

*

 The panel unanimously concludes this case is suitable for decision without oral argument. *685*See*Fed. R.App. P. 34(a)(2).

MEMORANDUM **

Surjit Singh, a native and citizen of India, petitions for review of the Board of Immigration Appeals’ order affirming an immigration judge’s decision denying his application for asylum, withholding of removal, and protection under the Convention Against Torture (“CAT”). We have jurisdiction under 8 U.S.C. § 1252. We review for substantial evidence, *Gonzalez-Hernandez v. Ashcroft,*336 F.3d 995, 998 (9th Cir.2003), and we deny the petition for review.

Substantial evidence supports the agency’s finding that, even if Singh established past persecution on account of a protected ground, the government rebutted the presumption of a well-founded fear of future persecution by establishing changed circumstances in India. *See*8 C.F.R. § 1208.13(b)(l)(i)(4) and (ii); *see also Gonzalez-Hernandez,*336 F.3d at 998-1001. The agency rationally construed evidence in the record and provided a sufficiently individualized analysis of Singh’s situation. *See id.*at 1000. Accordingly, Singh’s asylum claim fails.

Because Singh failed to establish eligibility for asylum, he necessarily failed to meet the more stringent standard for withholding of removal. *See id.*at 1001 n. 5.

Finally, substantial evidence also supports the agency’s denial of CAT relief because Singh failed to establish it is more likely than not he will be tortured if returned to India. *See*8 C.F.R. § 1208.16(c)(2); *Singh v. Gonzales,*439 F.3d 1100, 1113 (9th Cir.2006).

PETITION FOR REVIEW DENIED.

**

 This disposition is not appropriate for publication and is not precedent except as provided by 9th Cir. R. 36-3.
<PAGE>


                                                                    EXHIBIT 32.2


                              L Q CORPORATION, INC.
                CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
                       AS ADOPTED PURSUANT TO SECTION 906
                        OF THE SARBANES-OXLEY ACT OF 2002


In connection with the Quarterly Report of L Q Corporation, Inc. (the "Company")
on Form 10-Q for the period ended September 30, 2005, as filed with the
Securities and Exchange Commission on the date hereof (the "Report"), I, Melvyn
Brunt, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C.
Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of
2002, that:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of
the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material
respects, the financial condition and results of operations of the Company.

A signed original of this written statement required by Section 906 has been
provided to the Company and will be retained by the Company and furnished to the
Securities and Exchange Commission or its staff upon request.





Dated: November 14 , 2005


                                  /s/ Melvyn Brunt
                                  ----------------
                                  Melvyn Brunt
                                  Chief Financial Officer
ex4-4.htm


Exhibit 4.4

 

 

VISION-SCIENCES, INC.

 

December 21, 2014

 

Via FedEx

 

Lewis C. Pell

40 Ramland Road South

Orangeburg, NY 10962

 

	
Re:
	
Extension of Warrants



 

Dear Mr. Pell,

 

Reference is made to (a) that certain Common Stock Purchase Warrant, dated November 9, 2009, issued by Vision-Sciences, Inc. (the “Company”) to you for the purchase of 272,727 shares of common stock of the Company (“Common Stock”), (b) that certain Common Stock Purchase Warrant, dated November 9, 2009, issued by the Company to you for the purchase of 378,788 shares of Common Stock, (c) that that certain Common Stock Purchase Warrant, dated September 30, 2011, issued by the Company to you for the purchase of 1,229,105 shares of Common Stock (collectively with the warrants referenced in clause (a) and clause (b), the “Warrants”) and (d) those three (3) certain Amendments to Convertible Promissory Note (collectively the “Loan Amendments”), between you and the Company each dated as of the date hereof. 

 

In consideration for your entry into the Loan Amendments and the amendments to the Warrants hereinafter provided, the Company and you agree that the period during which the Warrants may be exercised is hereby amended to commence on the Holder Conversion Date (as defined in the Loan Amendments) and to end on the later of (i) the Maturity Date (as defined in the Loan Amendments) or (ii) the date that the Loans (as defined in Convertible Promissory Notes amended by the Loan Amendments) are paid in full or converted into shares of Common Stock in accordance with the Loan Amendments. In addition, the Warrants may also be exercised effective immediately prior to the closing of an event constituting a Change of Control (as defined in the Loan Amendments).

 

Except as otherwise set forth herein, the Warrants remain unmodified and in full force and effect. This letter supersedes and replaces the letter dated September 30, 2011 extending the Warrants referenced in clauses (a) and (b) above.

 

Please indicate your agreement to the terms of this letter by signing the enclosed copy of this letter where indicated below and returning it to Howard Zauberman at 40 Ramland Road South, Orangeburg, NY 10962.

  


 

 




 


  

	
 
	
Yours very truly, 

	
 
	
 
	 	
 

	
 
	
VISION-SCIENCES, INC.  

	
 
	
 
	 	
 

	
 
	
 
	 	
 

	
 
	
 
	 	
 

	
 
	
By: 
	/s/	
Howard Zauberman 

	
 
	
Name:
	
Howard Zauberman 

	
 
	
Title:
	
President and Chief Executive Officer 

	
 
	
 
	 	
 

	
 
	
Accepted and agreed to as of December 21, 2014 

	
 
	
 
	 	
 

	
 
	
 
	 	
 

	
 
	
/s/ Lewis C. Pell  

	
 
	
Lewis C. Pell
#### UNITED STATES of America, Plaintiff-Appellee, v. Jeffrey Alan ARTHUR, Defendant-Appellant.

No. 10-4700.

United States Court of Appeals, Fourth Circuit.

Submitted: March 31, 2011.

Decided: April 5, 2011.

Carol Ann Bauer, Morganton, North Carolina, for Appellant. Amy Elizabeth Ray, Assistant United States Attorney, Asheville, North Carolina, for Appellee.

Before NIEMEYER, SHEDD, and AGEE, Circuit Judges.

Affirmed by unpublished PER CURIAM opinion.

Unpublished opinions are not binding precedent in this circuit.

PER CURIAM:

Jeffrey Alan Arthur pled guilty to conspiracy to manufacture and possess with intent to distribute at least 500 grams of a mixture or substance containing methamphetamine. The Government moved for a downward departure from the statutory minimum of 240 months’ imprisonment. The court granted the motion and sentenced Arthur to 180 months’ imprisonment. On appeal, Arthur’s counsel has filed a brief pursuant to *Anders v. California,*386 U.S. 738, 87 S.Ct. 1396, 18 L.Ed.2d 493 (1967), concluding that there are no meritorious grounds for appeal, but questioning whether Arthur received ineffective assistance of counsel below. Arthur was informed of his right to file a pro se supplemental brief, but did not do so. The Government declined to file a responsive brief.

Counsel asks us to review whether Arthur received ineffective assistance of counsel because Arthur was allowed to plead guilty without fully understanding the potential punishment. Claims of ineffective assistance of counsel are generally not cognizable on direct appeal, unless counsel’s “ineffectiveness conclusively appears from the record.” *United States v. Baldovinos,*434 F.3d 233, 239 (4th Cir.2006). We conclude that the record does not conclusively demonstrate that counsel was ineffective. *See Strickland v. Washington,*466 U.S. 668, 687-88, 104 S.Ct. 2052, 80 L.Ed.2d 674 (1984). Accordingly, in order to allow for the adequate development of the record, Arthur must bring his *280claim in a 28 U.S.C.A. § 2255 (West Supp.2010) motion. *See United States v. Baptiste,*596 F.3d 214, 216-17 n. 1 (4th Cir.2010).

In accordance with *Anders,*we have thoroughly reviewed the entire record in this case and have found no meritorious issues for appeal. We therefore affirm Arthur’s conviction and sentence. This court requires that counsel inform Arthur, in writing, of the right to petition the Supreme Court of the United States for further review. If Arthur requests that a petition be filed, but counsel believes that such a petition would be frivolous, then counsel may move in this court for leave to withdraw from representation. Counsel’s motion must state that a copy thereof was served on Arthur. We dispense with oral argument because the facts and legal contentions are adequately presented in the materials before the court and argument would not aid the decisional process.

*AFFIRMED.*
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### National Institutes of Health

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:*                         National Eye Institute Special Emphasis Panel; NEI Clinician Scientist Mentored Training Grant Applications, K08 and K23.                    

*Date:*                         October 30-31, 2017.                    

*Time:*                         10:00 a.m. to 4:30 p.m.                    

*Agenda:*                         To review and evaluate grant applications.                    

*Place:*                         National Institutes of Health, 5635 Fishers Lane, Bethesda, MD 20892 (Virtual Meeting).                    

*Contact Person:*                         Anne E. Schaffner, Ph.D., Chief, Scientific Review Branch, Division of Extramural Research, National Eye Institute, 5635 Fishers Lane, Suite 1300, MSC 9300, Bethesda, MD 20892-9300, (301) 451-2020,                         *aes@nei.nih.gov.*

(Catalogue of Federal Domestic Assistance Program Nos. 93.867, Vision Research, National Institutes of Health, HHS)

Dated: October 4, 2017.

Natasha M. Copeland,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2017-21828 Filed 10-10-17; 8:45 am]

 BILLING CODE 4140-01-P
<TABLE> <S> <C>


<ARTICLE>                     5

<S>                             <C>
<PERIOD-TYPE>                   12-MOS
<FISCAL-YEAR-END>                              JUL-31-1998
<PERIOD-END>                                   JUL-31-1998
<CASH>                                         936,000
<SECURITIES>                                   0
<RECEIVABLES>                                  1,430,000
<ALLOWANCES>                                   0
<INVENTORY>                                    0
<CURRENT-ASSETS>                               2,761,000
<PP&E>                                         676,000
<DEPRECIATION>                                 249,000
<TOTAL-ASSETS>                                 12,956,000
<CURRENT-LIABILITIES>                          3,488,000
<BONDS>                                        0
<PREFERRED-MANDATORY>                          0
<PREFERRED>                                    0
<COMMON>                                       114,000
<OTHER-SE>                                     9,097,000
<TOTAL-LIABILITY-AND-EQUITY>                   12,956,000
<SALES>                                        0
<TOTAL-REVENUES>                               1,389,000
<CGS>                                          8,108,000
<TOTAL-COSTS>                                  17,746,000
<OTHER-EXPENSES>                               0
<LOSS-PROVISION>                               0
<INTEREST-EXPENSE>                             0
<INCOME-PRETAX>                                (2,940,000)
<INCOME-TAX>                                   1,837,000
<INCOME-CONTINUING>                            (4,777,000)
<DISCONTINUED>                                 0
<EXTRAORDINARY>                                0
<CHANGES>                                      0
<NET-INCOME>                                   (4,777,000)
<EPS-BASIC>                                    (.61)
<EPS-DILUTED>                                  (.61)



</TABLE>
Exhibit 32.2

Certification of Chief Financial Officer Pursuant to

18 U.S.C. Section 1350, as Adopted
Pursuant to

Section 906 of the Sarbanes-Oxley Act of 2002

I, Michael J. Lambert, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that
the Quarterly Report of Quest Software, Inc. on Form 10-Q for the three months ended March 31, 2006, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in
such Report fairly presents, in all material respects, the financial condition and results of operations of Quest Software, Inc.



|                   |  |  |  |     |  |                           |  |                                               
|------------------ |  |  |  | --- |  | ------------------------- |  | ----------------------------------------------
|                   |  |  | 
|Date: May 10, 2006 |  |  |  | By: |  | /S/    MICHAEL J. LAMBERT
|                   |  |  |  |     |  | Name:                     |  | Michael J. Lambert                            
|                   |  |  |  |     |  | Title:                    |  | Senior Vice President, Chief Financial Officer
----

Exhibit 12.1 

CERTIFICATION 

I, Richard J. Hall, certify that: 

1.     I havereviewed this annual report on Form 20-F of Metallica Resources Inc.; 

2.    Based on my knowledge, this report does not contain any untrue statement of amaterial fact or omit to state a material fact necessary to make the statementsmade, in light of the circumstances under which such statements were made, notmisleading with respect to the period covered by this report; 

3.    Based on my knowledge, the financial statements, and other financial informationincluded in this report, fairly present in all material respects the financialcondition, results of operations and cash flows of the company as of, and for,the periods presented in this report; 

4.    The company's other certifying officer and I are responsible for establishingand maintaining disclosure controls and procedures (as defined in Exchange ActRules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (asdefined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:

(a)  Designed such disclosure controls and procedures, or caused such disclosurecontrols and procedures to be designed under our supervision, to ensure thatmaterial information relating to the company, including its consolidatedsubsidiaries, is made known to us by others within those entities, particularlyduring the period in which this report is being prepared; 

(b)  Designed such internal control over financial reporting, or caused such internalcontrol over financial reporting to be designed under our supervision, toprovide reasonable assurance regarding the reliability of financial reportingand the preparation of financial statements for external purposes in accordancewith generally accepted accounting principles; 

(c)  Evaluated the effectiveness of the company's disclosure controls and proceduresand presented in this report our conclusions about the effectiveness of thedisclosure controls and procedures, as of the end of the period covered by thisreport based on such evaluation; and 

(d)  Disclosed in this report any change in the company's internal control overfinancial reporting that occurred during the period covered by the annual reportthat has materially affected, or is reasonably likely to materially affect, thecompany's internal control over financial reporting; and 

5.    The company's other certifying officer and I have disclosed, based on our mostrecent evaluation of internal control over financial reporting, to the company'sauditors and the audit committee of the company's board of directors (or personsperforming the equivalent functions): 

(a)   Allsignificant deficiencies and material weaknesses in the design or operation ofinternal control over financial reporting which are reasonably likely toadversely affect the company's ability to record, process, summarize and reportfinancial information; and 

(b)   Any fraud, whetheror not material, that involves management or other employees who have asignificant role in the company's internal control over financial reporting. 

Date: April 2, 2007 

/s/ Richard J. Hall Richard J. Hall, President and Chief Executive Officer 

----
EXHIBIT 23

                       CONSENT OF INDEPENDENT ACCOUNTANTS



We hereby consent to the incorporation by reference in this Annual Report on
Form 10-K of Featherlite Inc. for the year ended December 31, 1998 of our report
on the consolidated financial statements dated February 8, 1999 which appears on
page 26 of the annual report to shareholders for the year ended December 31,
1998.

We also consent to the incorporation by reference in the Registration Statement
on Form S-8 (No. 33-90860) of the Featherlite Inc. 1994 Stock Option Plan and
Registration Statement on Form S-3 (No. 333-65647) of our report, dated February
8, 1999, on the consolidated financial statements of Featherlite Inc., which
report is incorporated by reference in the Annual Report on Form 10-K for the
year ended December 31, 1998.




/s/ McGladrey & Pullen, LLP


Rochester, Minnesota
March 29, 1999
<PAGE>   1



                                                                    EXHIBIT 23.1

                        Consent of KPMG Peat Marwick LLP

                             ACCOUNTANTS' CONSENT




The Board of Directors
Medirisk, Inc.


We consent to incorporation by reference in the registration statement (No.
333-28541) on Form S-8 of Medirisk, Inc. of our reports dated February 6, 1998,
relating to the consolidated balance sheets of Medirisk, Inc. and subsidiaries
as of December 31, 1997 and 1996, and the related consolidated statements of
operations, stockholders' equity (deficit), and cash flows for each of the
years in the three-year period ended December 31, 1997, and the related
financial statement schedule, which reports appear in the 1997 annual report on
Form 10-K of Medirisk, Inc.




                                             /s/ KPMG PEAT MARWICK LLP


Atlanta, Georgia
May 19, 1998
<PAGE>

Exhibit 99.1



                            CERTIFICATION PURSUANT TO
                    SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

The undersigned, Gary Allanson, Chief Executive Officer of International
Dispensing Corporation, a Delaware corporation (the "Company"), and Edwin Tharp,
Chief Financial Officer of the Company, hereby certify, pursuant to Section 906
of the Sarbanes-Oxley Act of 2002, that:

     (1)  The Quarterly Report on Form 10-QSB of the Company for the period
          ended June 30, 2002, which this certification accompanies, fully
          complies with the requirements of section 13(a) or 15(d) of the
          Securities Exchange Act of 1934; and

     (2)  The information contained in the Report fairly presents, in all
          material respects, the financial condition and results of operations
          of the Company as of and for the periods presented in the Report.





August 13, 2002                            /s/ Gary Allanson
                                           -------------------------
                                           Gary Allanson
                                           Chief Executive Officer


August 13, 2002                            /s/Edwin Tharp
                                           -------------------------
                                           Edwin Tharp
                                           Chief Financial Officer


                                       15.